产品描述
| 溶解性 | DMSO |
| 存贮条件 | 储存温度-20°C |
| 产品介绍 | Trelagliptin 是高度选择性的长效的DPP-4抑制剂。 |
| 生化机理 |
Trelagliptin is a long acting dipeptidyl peptidase-4 (DPP-4) inhibitor that is being developed for the treatment of type 2 diabetes (T2D). Two Phase II clinical studies have been completed with Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus. Phase III clinical studies with trelagliptin in Japan to evaluate its safety and efficacy in a once-weekly oral treatment regimen. Currently, all available DPP-4 inhibitors are dosed once-daily. A once-weekly treatment, such as trelagliptin, would provide patients with a convenient treatment alternative and has the potential to improve treatment compliance. |
| 别名 | SYR-472;SYR472;SYR 472;曲格列汀;SYR-472;SYR472;SYR 472;(R)-2-[[6-(3-Aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl]methyl]-4-fluorobenzonitrile |
